From 2026-03-02 session.
Solventum reported fourth quarter 2025 adjusted earnings per share of $1.57, beating Wall Street estimates of $1.50. Revenue came in at $2 billion, exceeding analyst expectations of $1.96 billion. The company announced a $1 billion share repurchase program and provided 2026 guidance of $6.40 to $6.60 per share, above consensus estimates of $6.34.
What happened. Why it matters. 30 seconds.
Solventum is a healthcare products company spun off from 3M in 2024, making wound dressings, sterilization devices, medical tape, dental materials, and revenue cycle management software. It generates roughly $8 billion in annual revenue, with its MedSurg segment accounting for more than half of sales. The stock is currently navigating post-spinoff portfolio restructuring — including the divestiture of its purification unit to ThermoFisher — while absorbing margin pressure from tariffs and ERP transition costs flagged in its latest earnings report.
We watch SOLV for moves that stand out from normal trading -- the kind of day that makes you ask "WTF just happened?" When Solventum Corporation moves beyond its usual range, our AI digs through 15-20 news sources to piece together what drove it. No predictions, no trading advice -- just a clear explanation in about 30 seconds.
From a recent analysis